Pregnancy/Implantation Rates Using a Day 3 Score Versus Graduated Embryo Score Plus a Biochemical Marker (sHLA-G)
NCT ID: NCT00680238
Last Updated: 2008-05-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
214 participants
INTERVENTIONAL
2004-06-30
2007-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Predictive Value of Embryonic Testing
NCT03604107
Hyaluronan-enriched Medium and Euploid Blastocyst Transfers
NCT06165367
Study of the Efficacy of 24 Chromosome Preimplantation Genetic Diagnosis (PGD)
NCT01219283
Single Embryo TrAnsfeR of Euploid Embryo
NCT02268786
Correlating Time-Lapse Parameters With aCGH Testing in IVF Treatment (aCGH Study)
NCT02141685
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
A
Embryo selection for transfer based on a Day 3 score only.
Human derived FSH
Customized for each patient
B
Embryos for transfer by first selecting any embryos that had a positive sHLA-G expression of OD = 190 ±6 and correlating such with the highest GES score available.
Human derived FSH
Customized for each patient
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Human derived FSH
Customized for each patient
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Specific Immunologic factors
25 Years
40 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Stellenbosch
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Stellenbosch University
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Thinus Kruger, M.D. PhD.
Role: STUDY_DIRECTOR
University of Stellenbosch
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
DKotze
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.